Multiparameter prediction of myeloid neoplasia risk
Muxin Gu(Wellcome/MRC Cambridge Stem Cell Institute), George S. Vassiliou(Wellcome/MRC Cambridge Stem Cell Institute), Ludovica Marando(Wellcome/MRC Cambridge Stem Cell Institute), Clea Bárcena(Universidad de Oviedo), William G. Dunn(Wellcome/MRC Cambridge Stem Cell Institute), Irina Mohorianu(Wellcome/MRC Cambridge Stem Cell Institute), Margarete A. Fabre(AstraZeneca (United Kingdom)), Luca Malcovati(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Siddhartha Kar(University of Cambridge), Catherine Cargo(St James's University Hospital), Alexandra Smith(Yorkshire Cancer Research), Moritz Gerstung(European Bioinformatics Institute), Sruthi Cheloor Kovilakam(Wellcome/MRC Cambridge Stem Cell Institute), Pedro M. Quirós(Universidad de Oviedo)
Cited by 107
Related Papers
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
|The Lancet|2005|3.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k